Dose-dependent hematopoietic stem cell repopulating advantage in CXB-12 mice
| Months . | CXB-12:CByB6F1 BMC ratio . | |||
|---|---|---|---|---|
| 5 × 104:5 × 105 | 106:107 | 3 × 106:107 | 4 × 106:2 × 106 | |
| % CXB-12 cells* | ||||
| 1 | 10.2 ± 1.3 | 29.0 ± 4.0 | 66.0 ± 13.3 | 90.4 ± 2.8 |
| 3 | 19.5 ± 2.5 | 39.8 ± 2.7 | 82.6 ± 8.9 | 98.4 ± 1.3 |
| 6 | 21.9 ± 2.9 | 39.0 ± 2.4 | 78.5 ± 9.3 | 95.8 ± 2.5 |
| Expected CXB-12:CByB6F1 RUs (% CXB-12) without CXB-12 repopulating advantage† | ||||
| 0.5:5 (9.1) | 10:100 (9.1) | 30:100 (23.1) | 40:20 (66.7) | |
| Observed CXB-12:CByB6F1 RUs‡ | ||||
| 1 | 0.6:5 (1.2) | 41:100 (4.1) | 194:100 (6.4) | 188:20 (4.7) |
| 3 | 1.2:5 (2.4) | 66:100 (6.6) | 474:100 (16) | 1232:20 (31) |
| 6 | 1.4:5 (2.8) | 64:100 (6.4) | 366:100 (12) | 456:20 (11) |
| Months . | CXB-12:CByB6F1 BMC ratio . | |||
|---|---|---|---|---|
| 5 × 104:5 × 105 | 106:107 | 3 × 106:107 | 4 × 106:2 × 106 | |
| % CXB-12 cells* | ||||
| 1 | 10.2 ± 1.3 | 29.0 ± 4.0 | 66.0 ± 13.3 | 90.4 ± 2.8 |
| 3 | 19.5 ± 2.5 | 39.8 ± 2.7 | 82.6 ± 8.9 | 98.4 ± 1.3 |
| 6 | 21.9 ± 2.9 | 39.0 ± 2.4 | 78.5 ± 9.3 | 95.8 ± 2.5 |
| Expected CXB-12:CByB6F1 RUs (% CXB-12) without CXB-12 repopulating advantage† | ||||
| 0.5:5 (9.1) | 10:100 (9.1) | 30:100 (23.1) | 40:20 (66.7) | |
| Observed CXB-12:CByB6F1 RUs‡ | ||||
| 1 | 0.6:5 (1.2) | 41:100 (4.1) | 194:100 (6.4) | 188:20 (4.7) |
| 3 | 1.2:5 (2.4) | 66:100 (6.6) | 474:100 (16) | 1232:20 (31) |
| 6 | 1.4:5 (2.8) | 64:100 (6.4) | 366:100 (12) | 456:20 (11) |
Recipients were natural killer cell–depleted, lethally irradiated, young CByB6F1 hybrids. Cells descended from CXB-12 donor and CByB6F1 competitors were distinguished by their Gpi1 marker. Mean ± SE are given for 37 recipients per donor for the 5 × 104:5 × 105 donor:competitor ratio from the experiment detailed in Figure 3; for 4 recipients per donor in a second experiment for the 106:107 and 3 × 106:107 ratios; and for 8 recipients per donor for the 4 × 106:2 × 106 ratio from the experiment in Figure 1.
RU indicates repopulating unit.
Average of erythrocytes and lymphocytes.
The RU is defined as 1 per 105 BMCs for CByB6F1 competitors.
Fold CXB-12 advantage.